Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis.

Xu H et al. · ncbi_pmc

NCBI PubMed Central · Papers · License: Open Access

behavioral economics

Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.

Record · ID 4442 · SHA-256 f6818059ea7e047a
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.